Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Epoetin beta may cause the body to make more red blood cells and may prevent or reduce side effects in patients undergoing chemotherapy for solid tumors.

PURPOSE: This clinical trial is studying how well epoetin beta works in patients undergoing chemotherapy for solid tumors.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
• Treatments: Epoetin Alfa

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of solid tumor

• Hemoglobin 9-11 g/dL

• Planning to receive epoetin beta for ≥ 8 weeks while undergoing chemotherapy for cancer

PATIENT CHARACTERISTICS:

• WHO performance status 0-2

• Not pregnant or nursing

• Not incarcerated or under guardianship

• No psychological, familial, social, or geographical reason that would preclude study follow-up

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• More than 6 months since prior epoetin

• No concurrent chemoradiotherapy